Director – Early Development
Tarsus Pharmaceuticals
Director – Early Development
Tarsus Pharmaceuticals
Develops FDA-approved ophthalmic therapies
Hi Tarsan!
Thanks for your interest in this position. Please review the details and if role and if it's something that could match your career goals, connect with your current manager and HRBP to discuss if your experience and skills line up. If everything is a go, please apply and the Talent Acquisition team will contact you for an interview so we can also get to know you better.
- Your Human Resources Team
About the Role
The Director, Early Development - Clinical Sciences will create early development clinical plans, program outlines, study designs and clinical study essential documents. This individual will be accountable for leading the cross-functional Study Teams to meet study deliverables and represent clinical development in core team and investigator meetings as needed.
This role will collaborate closely with cross-functional teams such as Clinical Operations, Regulatory Affairs, Medical Affairs, CMC, Finance and Legal to drive efficient and scientifically rigorous early development clinical work.
Let’s talk about some of the key responsibilities of the role:
Factors for Success:
Leadership Competencies - This role requires mastery of the Tarsus Leadership Competencies for Leading People, including:
Few Other Details Worth Mentioning:
At Tarsus, we understand the importance of attracting and retaining top talent. The expected base pay range for this position is $203,200 - $284,600 plus bonus, stock equity, and comprehensive benefits. The base pay range reflects the target range for this position, but individual pay will be determined by additional factors such as job-related skills, experience and relevant education or training. Our benefits include health, dental and vision insurance benefits to ensure your well-being. We believe in work-life balance and offer generous paid time off, including vacation, holidays, and personal days. For more details regarding Tarsus benefits, please visit: https://eb.alliant.com/26tarsusbenefitssnapshot.
#LI-Remote
Develops FDA-approved ophthalmic therapies
Tarsus Pharmaceuticals develops and markets treatments for eye care and infectious diseases, including XDEMVY (lotilaner ophthalmic solution 0.25%), an FDA-approved eye drop for Demodex Blepharitis. The product is applied as a medicated eye drop to kill Demodex mites and relieve eyelid inflammation. The company differentiates itself with a focused ocular/infectious-disease portfolio, an FDA-approved therapy, and active partnerships to expand its research and reach. Its goal is to address unmet medical needs, grow its product lineup through commercialization, and pursue new indications in eye care and infectious diseases.
Explore more opportunities at Tarsus Pharmaceuticals